Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Repligen Corporation (RGEN)

NASDAQ: RGEN · Biological Products, (No Diagnostic Substances) · Waltham, MA

Our rating: Neutral

Call changed from Cautious to Neutral at $172.95, moderate conviction, November 2, 2026.

Breaks if: The Neutral view turns Cautious if year-over-year revenue growth decelerates below 10% in either of the next two reported quarters, signaling the recovery thesis is losing steam at a multiple this demanding. It turns Positive if revenue growth holds above 25% for two consecutive quarters and trailing FCF reaches $150M or more within four quarters, indicating that underlying earnings power is closing the gap with the market capitalization at a visible pace.

Key figures

Market value$10.5B
Revenue, last 12 months$806M
Net income, last 12 months−$12M
Free cash flow, last 12 months$107M
Price to earningsn/a
Free cash flow yield1.0%
Dividend yield0.0%
Operating margin2.3%
Return on equity−0.6%
Beta to the S&P 5001.30
Volatility, annualized50.3%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$209M10.9%$-0.68$38M
June 30, 2026$204M11.9%$0.09$27M
March 31, 2026$194M14.8%$0.15$24M
December 31, 2025$198M18.1%$0.23$18M
September 30, 2025$189M21.9%$0.26$43M
June 30, 2025$182M14.8%$0.26$22M
March 31, 2025$169M10.4%$0.10$11M
December 31, 2024$168M0.6%$-0.61$34M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

15 ledger entries and 64 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.